Cargando…

Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation

In this review, we summarize the recently published literature that demonstrates the efficacy and safety of autologous haematopoietic stem cell therapy (AHSCT) in multiple sclerosis (MS) and highlight the importance of supportive care required for the safe and well-tolerated delivery of AHSCT. RECEN...

Descripción completa

Detalles Bibliográficos
Autores principales: Ismail, Azza, Sharrack, Basil, Saccardi, Riccardo, Moore, John J., Snowden, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867671/
https://www.ncbi.nlm.nih.gov/pubmed/31599815
http://dx.doi.org/10.1097/SPC.0000000000000466
_version_ 1783472118433841152
author Ismail, Azza
Sharrack, Basil
Saccardi, Riccardo
Moore, John J.
Snowden, John A.
author_facet Ismail, Azza
Sharrack, Basil
Saccardi, Riccardo
Moore, John J.
Snowden, John A.
author_sort Ismail, Azza
collection PubMed
description In this review, we summarize the recently published literature that demonstrates the efficacy and safety of autologous haematopoietic stem cell therapy (AHSCT) in multiple sclerosis (MS) and highlight the importance of supportive care required for the safe and well-tolerated delivery of AHSCT. RECENT FINDINGS: MS is an autoimmune inflammatory and degenerative disorder of the central nervous system (CNS). In the majority of patients, the illness runs a relapsing remitting course (RRMS), culminating in a secondary progressive phase with gradual accumulation of fixed disabilities. Currently available disease-modifying therapies suppress CNS inflammation but have a limited effect on preventing disease progression for which there remains no effective therapy. Over the last two decades, there has been increasing evidence that AHSCT is a highly effective therapeutic strategy for treatment-resistant inflammatory types of MS, especially RRMS. Concerns about the safety of AHSCT in MS, usually a nonlife-threatening disease, have previously limited its use. However, AHSCT can now be delivered safely with major long-term benefits because of increasing transplant centre experience, judicious patient selection and good supportive care. SUMMARY: MS is currently the fastest growing indication for AHSCT in Europe. Supportive care before, during and after the transplant period is key to the successful delivery of AHSCT.
format Online
Article
Text
id pubmed-6867671
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-68676712020-01-23 Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation Ismail, Azza Sharrack, Basil Saccardi, Riccardo Moore, John J. Snowden, John A. Curr Opin Support Palliat Care BLOOD, BONE MARROW AND LYMPHATICS: Edited by Christopher Dalley In this review, we summarize the recently published literature that demonstrates the efficacy and safety of autologous haematopoietic stem cell therapy (AHSCT) in multiple sclerosis (MS) and highlight the importance of supportive care required for the safe and well-tolerated delivery of AHSCT. RECENT FINDINGS: MS is an autoimmune inflammatory and degenerative disorder of the central nervous system (CNS). In the majority of patients, the illness runs a relapsing remitting course (RRMS), culminating in a secondary progressive phase with gradual accumulation of fixed disabilities. Currently available disease-modifying therapies suppress CNS inflammation but have a limited effect on preventing disease progression for which there remains no effective therapy. Over the last two decades, there has been increasing evidence that AHSCT is a highly effective therapeutic strategy for treatment-resistant inflammatory types of MS, especially RRMS. Concerns about the safety of AHSCT in MS, usually a nonlife-threatening disease, have previously limited its use. However, AHSCT can now be delivered safely with major long-term benefits because of increasing transplant centre experience, judicious patient selection and good supportive care. SUMMARY: MS is currently the fastest growing indication for AHSCT in Europe. Supportive care before, during and after the transplant period is key to the successful delivery of AHSCT. Lippincott Williams & Wilkins 2019-12 2019-10-31 /pmc/articles/PMC6867671/ /pubmed/31599815 http://dx.doi.org/10.1097/SPC.0000000000000466 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle BLOOD, BONE MARROW AND LYMPHATICS: Edited by Christopher Dalley
Ismail, Azza
Sharrack, Basil
Saccardi, Riccardo
Moore, John J.
Snowden, John A.
Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation
title Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation
title_full Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation
title_fullStr Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation
title_full_unstemmed Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation
title_short Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation
title_sort autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the autoimmune diseases working party of the european society for blood and marrow transplantation
topic BLOOD, BONE MARROW AND LYMPHATICS: Edited by Christopher Dalley
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867671/
https://www.ncbi.nlm.nih.gov/pubmed/31599815
http://dx.doi.org/10.1097/SPC.0000000000000466
work_keys_str_mv AT ismailazza autologoushaematopoieticstemcelltherapyformultiplesclerosisareviewforsupportivecarecliniciansonbehalfoftheautoimmunediseasesworkingpartyoftheeuropeansocietyforbloodandmarrowtransplantation
AT sharrackbasil autologoushaematopoieticstemcelltherapyformultiplesclerosisareviewforsupportivecarecliniciansonbehalfoftheautoimmunediseasesworkingpartyoftheeuropeansocietyforbloodandmarrowtransplantation
AT saccardiriccardo autologoushaematopoieticstemcelltherapyformultiplesclerosisareviewforsupportivecarecliniciansonbehalfoftheautoimmunediseasesworkingpartyoftheeuropeansocietyforbloodandmarrowtransplantation
AT moorejohnj autologoushaematopoieticstemcelltherapyformultiplesclerosisareviewforsupportivecarecliniciansonbehalfoftheautoimmunediseasesworkingpartyoftheeuropeansocietyforbloodandmarrowtransplantation
AT snowdenjohna autologoushaematopoieticstemcelltherapyformultiplesclerosisareviewforsupportivecarecliniciansonbehalfoftheautoimmunediseasesworkingpartyoftheeuropeansocietyforbloodandmarrowtransplantation